Bayer Intellectual Property GmbH & Anor v Sandoz AG & Anor

Link copied
Case Copied 1 min read

BAYER INTELLECTUAL PROPERTY GMBH & ANOR

v

SANDOZ AG & ANOR

[2025] HCADisp 45

M106/2024

  1. The applicants seek special leave to appeal from the whole of the judgment of the Full Court of the Federal Court of Australia (Yates, Burley and Downes JJ), allowing an appeal of the respondents from a judgment of the Federal Court of Australia (Rofe J).

  2. The application does not raise an issue of principle sufficient to warrant a grant of special leave and the proposed appeal has insufficient prospects of success.

  3. Special leave to appeal is refused with costs.

    Gageler CJ
    Gordon J
    Edelman J
    Steward J
    Gleeson J
    Jagot J
    Beech-Jones J

    6 March 2025

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Bayer Intellectual Property GmbH & Anor v Sandoz AG & Anor and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2025] HCADisp 45
Decision Date

CaseChat Overview and Summary

In the recent case of Bayer Intellectual Property GmbH & Anor v Sandoz AG & Anor, the applicants sought special leave to appeal from the whole of the judgment rendered by the Full Court of the Federal Court of Australia. The case revolves around an intellectual property dispute concerning the patentability of a pharmaceutical product. The applicants, Bayer Intellectual Property GmbH and another, sought to appeal against the respondents, Sandoz AG and another, who had successfully appealed a decision made by Rofe J in the Federal Court of Australia.

The central legal issues that the court had to decide pertained to the interpretation and application of Australian patent law, particularly in relation to the patentability of the pharmaceutical product in question. The applicants argued that the Full Court had erred in its interpretation of the relevant statutory provisions and in the application of the principles governing the patentability of pharmaceutical products. The court had to determine whether the Full Court’s judgment contained any errors of law that warranted an appeal to the High Court.

The High Court considered the merits of the application for special leave to appeal and assessed whether the case raised an issue of principle sufficient to warrant a grant of special leave. The court examined the reasoning and conclusions of the Full Court, as well as the potential impact of the case on the broader principles of patent law. After careful consideration, the High Court found that the proposed appeal had insufficient prospects of success and that the application did not raise an issue of principle that warranted special leave to appeal. Consequently, the High Court refused special leave to appeal, with costs awarded to the respondents.

Orders

Orders of the court

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established